Release Date: May 29, 2025
Expiration Date: May 29, 2026
Activity Overview
This online, on-demand virtual symposium brings together experts in dry eye disease (DED). In this educational program, these experts share insights into recent neuromodulation opportunities in DED, as well as emerging mechanisms of action, such as targeting TRPM8 thermoreceptors to stimulate tear production.
This educational activity is an archive of the live symposium held on April 25, 2025.
Target Audience
This educational activity is directed toward ophthalmologists and other eye care professionals involved in the management of patients with dry eye disease (DED).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the neural network that monitors the ocular surface environment and regulates tear secretion
- Assess the mechanisms of action of neuromodulation therapeutics in dry eye disease (DED)
- Evaluate current and emerging therapeutics for DED
- Identify clinical applications and patient selection for neuromodulation therapies in DED
Marjan Farid, MD
Director of Cornea, Cataract, and Refractive Surgery
Vice-Chair of Ophthalmic Faculty
Professor of Ophthalmology
University of California Irvine
Irvine, CA
Disclosures: Dr Farid has no financial relationships to disclose.
John Hovanesian, MD
President, Harvard Eye Associates
Laguna Hills, CA
Clinical Faculty, UCLA Jules Stein Eye Institute
Los Angeles, CA
Disclosures: Grant/Research Support: AcuFocus, Aerie, Alcon, Allergan, Bausch + Lomb, Cord LLC, EyePoint, Glaukos, Imprimis, Johnson & Johnson Vision, Novartis, Omeros, On Point Vision, Research Insight LLC, Sight Sciences, Sun Pharma, Zeiss; Consultant: AcuFocus, Aerie, Alcon, Allergan, Apellis, Avellino Labs USA, Azura Opthalmics, BlephEx, Bruder Healthcare, BVI, Centricity Vision, Cloudbreak Therapeutics, Cord LLC, CorneaGen, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, GSK, Hasa Optix, Horizon Therapeutics, Hoya, Imprimis, Johnson & Johnson Vision, Kala, Novartis, Ocular Therapeutix, Oculis, Omeros, On Point Vision, Orasis, Oyster Point Pharma, Rayner, Research Insight LLC, Sensimed, SightLife, Sun Pharma, Tarsus, TearLab, Thea Pharma, Touch Opthalmology, Trefoil Therapeutics, Vindico Medical Education, Visus, Zeiss; Other: Alcon, Alicia Surgery Center, Allegro Opthalmics, Allergan, Apellis, Bausch + Lomb, BlephEx, Bruder Healthcare, BVI, Cloudbreak Therapeutics, Cord LLC, CorneaGen, Crisper, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, Guardion Health Sciences, Harvard Eye Associates, Hasa Optix, Horizon Therapeutics, Hoya, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Omeros, Orasis, Research InSight LLC, RxSight, Sight Sciences, SightLife, Slack Books, Sun Pharma, Tarsus, Tear Clear, Trefoil Therapeutics, Versant Ventures and its investments, Visionary Ventures Fund 1 and 2 and its investments, Visus, Zeiss
Beeran Meghpara, MD
Director of Refractive Surgery
Wills Eye Hospital
Clinical Assistant Professor of Ophthalmology
Thomas Jefferson University School of Medicine
Philadelphia, PA
Disclosures: Consultant; Alcon, Allergan, BioTissue, Dompé, Glaukos, Gore, Johnson & Johnson Vision, Kala, Oculus, Orasis, Sight Sciences, Sun Pharma, Tarsus, Théa, Zeiss; Speakers Bureau; Alcon, Dompé, Johnson & Johnson Vision, Sun Pharma
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.